+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID04674449

International Study of Coronary Microvascular Angina iCorMicA a Randomised, Controlled, Multicentre Trial and Registry

Led by NHS Greater Glasgow and Clyde · Updated on 2026-04-09

1500

Participants Needed

39

Research Sites

235 weeks

Total Duration

On this page

Sponsors

N

NHS Greater Glasgow and Clyde

Lead Sponsor

U

University of Glasgow

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.

CONDITIONS

Brief Title

iCorMicA - Stratified Medicine in Angina

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Planned clinical invasive coronary angiography
  • Symptoms of angina (typical or atypical) based on Rose and/or Seattle Angina questionnaires
  • Ability to comply with study procedures
  • Able to give informed consent
Not Eligible

You will not qualify if you...

  • Non-coronary primary reason for invasive angiography (e.g., valve disease or heart failure)
  • History of coronary artery bypass surgery
  • Presence of obstructive coronary artery disease (stenosis >50% in a main artery >2.5 mm or fractional flow reserve 60.80)
  • Logistical reasons preventing participation (patients with these enter a follow-up registry)

Research Team

C

Colin Berry, MBChB, PhD

D

Daniel Ang, MBChB

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here